Although only a randomized trial can definitively answer this question (use of DPP4 inhibitors in patients with COVID-19), based on molecular, pathophysiological, and retrospective studies, the use of iDPP4 is safe, and is certainly beneficial in metabolic control and can probably reduce the severity of COVID-19. This evidence concerns the gene DPP4 and COVID-19.